These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 16724693)
1. Clinical significance of serum p53 antibodies in oral cancer. Sainger RN; Shah MH; Desai AA; Shukla SN; Shah PM; Telang SD; Patel PS Tumori; 2006; 92(2):134-9. PubMed ID: 16724693 [TBL] [Abstract][Full Text] [Related]
2. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133 [TBL] [Abstract][Full Text] [Related]
3. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma. Yamazaki Y; Chiba I; Ishikawa M; Satoh C; Notani K; Ohiro Y; Totsuka Y; Mizuno S; Kitagawa Y Odontology; 2008 Jul; 96(1):32-7. PubMed ID: 18661202 [TBL] [Abstract][Full Text] [Related]
4. Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Kaur J; Srivastava A; Ralhan R Int J Cancer; 1997 Dec; 74(6):609-13. PubMed ID: 9421357 [TBL] [Abstract][Full Text] [Related]
5. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity. Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472 [TBL] [Abstract][Full Text] [Related]
7. Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions. Porrini R; Vercellino V; Rocchetti V; Renò F; Giorda E; Pomato E; Cannas M; Sabbatini M Minerva Stomatol; 2010 May; 59(5):233-9, 239-43. PubMed ID: 20502428 [TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer. Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470 [TBL] [Abstract][Full Text] [Related]
9. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. Rosenfeld MR; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real FX; Posner JB; Dalmau J J Natl Cancer Inst; 1997 Mar; 89(5):381-5. PubMed ID: 9060960 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma. Suzuki T; Yajima S; Ishioka N; Nanami T; Oshima Y; Washizawa N; Funahashi K; Otsuka S; Nemoto T; Shimada H Esophagus; 2018 Oct; 15(4):294-300. PubMed ID: 29959634 [TBL] [Abstract][Full Text] [Related]
11. Prognostic role of serum p53 antibodies in lung cancer. Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692 [TBL] [Abstract][Full Text] [Related]
12. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664 [TBL] [Abstract][Full Text] [Related]
13. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Girod SC; Pfeiffer P; Ries J; Pape HD Br J Oral Maxillofac Surg; 1998 Aug; 36(4):252-60. PubMed ID: 9762452 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy. Blanchard P; Quero L; Pacault V; Schlageter MH; Baruch-Hennequin V; Hennequin C BMC Cancer; 2012 Mar; 12():119. PubMed ID: 22448886 [TBL] [Abstract][Full Text] [Related]
15. Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Mayerhofer K; Tempfer C; Kucera E; Hefler L; Zeisler H; Kainz C; Zeillinger R; Sliutz G Anticancer Res; 1999; 19(1B):875-8. PubMed ID: 10216509 [TBL] [Abstract][Full Text] [Related]
16. Detection of circulating anti-p53 antibodies in esophageal cancer patients. Hagiwara N; Onda M; Miyashita M; Sasajima K J Nippon Med Sch; 2000 Apr; 67(2):110-7. PubMed ID: 10754600 [TBL] [Abstract][Full Text] [Related]
17. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. Shimada H; Shiratori T; Takeda A; Matsushita K; Okazumi S; Akutsu Y; Matsubara H; Nomura F; Ochiai T World J Surg; 2009 Feb; 33(2):272-7. PubMed ID: 19052812 [TBL] [Abstract][Full Text] [Related]
18. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857 [TBL] [Abstract][Full Text] [Related]
19. Circulating Anti-Matrix Metalloproteinase-7 Antibodies May Be a Potential Biomarker for Oral Squamous Cell Carcinoma. Jiang T; Xie P; Liu H J Oral Maxillofac Surg; 2016 Mar; 74(3):650-7. PubMed ID: 26454036 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of serum sialic acid, sialyltransferase and sialoproteins in oral cavity cancer. Raval GN; Patel DD; Parekh LJ; Patel JB; Shah MH; Patel PS Oral Dis; 2003 May; 9(3):119-28. PubMed ID: 12945593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]